DarioHealth Launching New Social Initiative at ADA's 77th Scientific Sessions
Digital health leader DarioHealth to unveil DarioCares™ plan in effort to give back to the community and raise diabetes awareness
Jun 5, 2017
CAESAREA, Israel, June 5, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it is launching a new social initiative called DarioCares™ at the American Diabetes Association's (ADA) 77th Scientific Sessions in San Diego later this week.
The aim of DarioCares™ is to leverage DarioHealth's compelling offerings and to raise funds for charitable and non-profit organizations working in the field of diabetes. DarioHealth will donate a portion of the proceeds of every sale made from this channel to organizations that will participate in our DarioCares™ plan. DarioHealth is currently in discussions with various organizations that may participate in the DarioCares™ program. In addition, DarioHealth intends to work closely with each participating organization to fine tune the right messaging in effort to maximize the impact of diabetes awareness.
Organizations that are accepted into the DarioCares™ program will have an unprecedented opportunity to raise diabetes awareness and further their cause by promoting the acclaimed Dario™ Blood Glucose Monitoring System. The all-in-one blood glucose meter and native smartphone app provides people with diabetes and pre-diabetes with a unique method to check their blood glucose levels via their iPhone.
Erez Raphael, Chairman and CEO of DarioHealth, commented, "The ADA conference is one of the biggest annual events in the diabetes industry. Many NGOs will be there and we look forward to strengthening our relationships with them and raising diabetes awareness. Furthermore, DarioCares™ is an excellent chance to play an active role with leading organizations that are driving change for people with diabetes. This is a win-win opportunity where we can make a significant contribution to the diabetes community."
For more information about DarioCares™, please visit DarioHealth at the ADA in booth 443. The ADA's 77th Scientific Sessions will take place June 9 - 13, 2017, at the San Diego Convention Center in San Diego, California.
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital health company serving tens of thousands of users with dynamic mobile health solutions. We believe people deserve the best tools to manage their treatment, and harnessing big data, we have developed a unique way for our users to analyze and personalize their diabetes management. With our smart diabetes solution, users have direct access to track and monitor all facets of diabetes, without having the disease slow them down. The acclaimed Dario™ Blood Glucose Monitoring System all-in-one blood glucose meter and native smartphone app gives users an unrivaled method for self-diabetes management. DarioHealth is headquartered in Caesarea, Israel with a regional office in Burlington, Massachusetts. For more information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company describes the launch of its DarioCares™ plan and its contributions and the Company's intention to donate a portion of the proceeds of every sale made through the DarioCares™ plan to participating organizations, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate and Media Contact
DarioHealth Investor Relations Contact
Rob Fink / Brett Maas
646-415-8972 / 646-536-7331
SOURCE DarioHealth Corp.